NantKwest
  • About
    • Company
    • Leadership
    • Board of Directors
  • Technology
    • Platform
    • Manufacturing
    • haNK
    • taNK
    • t-haNK
    • Posters
    • Publications
  • Clinical Trials
    • Pipeline
    • Nant Cancer Vaccine
  • News
    • Press Releases
    • Articles
    • Events
    • Presentations
  • Investors
    • Overview
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
      • Stock Calculator
    • News
    • Events & Presentations
    • Financials
      • SEC Filings
      • Annual Reports
      • Quarterly Reports
    • Corporate Governance
      • Governance Highlights
      • Management Team
      • Board of Directors
      • Committee Composition
    • Investor FAQs
    • Contact Us
  • Careers
    • Join Our Kwest
    • We’re Hiring
  • Contact
  • Patients
Select Page

ImmunityBio Announces Primary Endpoint Met of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 72% Complete Response Rate

Dec 20, 2020 | Press Releases

ImmunityBio Announces Primary Endpoint Met of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 72% Complete Response Rate  QUILT 3.032 study completes planned enrollment of BCG unresponsive non-muscle invasive bladder cancer CIS cohort...

IMMUNITYBIO AND NANTKWEST TO MERGE, CREATING A LEADING IMMUNOTHERAPY AND CELL THERAPY COMPANY

Dec 20, 2020 | Press Releases

Merged entity brings together 11 Phase II / III clinical trials across oncology and infectious disease that use combined immunotherapy platforms Broad late-stage pipeline for solid tumors including bladder, lung, breast, and pancreatic in addition to infectious...

ImmunityBio’s hAd5 T-Cell COVID-19 Vaccine Candidate Shows Complete Protection of Airways in Non-Human Primates

Dec 10, 2020 | Press Releases

BARDA-sponsored study shows second-generation hAd5 vaccine candidate in both subcutaneous and room temperature oral formulations inhibits SARS-CoV-2 virus replication to undetectable levels and clears infection within days in 100% of vaccinated non-human primates The...

ImmunityBio Announces Publication of Preclinical Data Demonstrating IL-15 Superagonist N-803 Improves Natural Killer-Mediated Tumor Cell Killing

Nov 23, 2020 | Press Releases

N-803 Boosts CD34+ Progenitor-Derived NK Cell Expansion and Functionality Adding N-803 to NK Cell Therapy has Potential to Improve Cancer Immunotherapy CULVER CITY Calif., November 23, 2020 — ImmunityBio, a privately-held immunotherapy company, today announced the...

NantKwest to Participate in the 32nd Annual Piper Sandler Healthcare Conference

Nov 18, 2020 | Press Releases

EL SEGUNDO, Calif., November 18, 2020 – NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced its participation in the virtual 32nd Annual Piper Sandler Healthcare conference, which takes place December 1-3,...

ImmunityBio, NantKwest Announce Positive Interim Phase 1 Safety Data of hAd5 COVID-19 Vaccine Dose Study

Nov 10, 2020 | Press Releases

First two cohorts fully enrolled; Low dose cohort reports no serious adverse events (SAEs), high dose cohort safety analysis ongoingSubject screening is ongoing for Phase I expansion cohortsPhase 2 / 3 hAd5 COVID-19 trial in designCULVER CITY & EL SEGUNDO,...
« Older Entries
Next Entries »

Categories

  • Articles
  • Press Releases

Current Events

Events

Archives

  • Facebook
  • Twitter

  © 2021 NantKwest. All Rights Reserved. A member of the NantWorks ecosystem of companies Privacy Policy | Legal Notice | Patent Notice
‘Nantkwest’, ‘aNK’, 'haNK', 'taNK', ‘vaNK’, 't-haNK', 'NK-92', ‘Neukosome’, 'Living Drugs in a Bag', and ‘Nature’s First Responder’ are trademarks or registered trademarks of Nantkwest, Inc.

The Natural Killer Cell platform consists of investigational agents that are restricted by federal law to investigational use only.

The Natural Killer Cell platform is being investigated in multiple clinical trials across tumor sites.

The content of this website is protected by Title 17 of the U.S. Code and may not be reproduced in whole or in part by any means.